If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
Medicago and GSK collaborated on Covifenz, an adjuvanted plant-based vaccine
The first wave of shipments includes several countries, such as Germany, France and Austria
The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad
he financing was significantly oversubscribed with high demand from both existing and new investors.
The facility will manufacture its Herceptin biosimilar, Tuznue
Therapeutic use of the product is for short term symptomatic relief of colds, chills and influenza including chesty coughs
The transaction as well as the open offer is expected to be completed by June this year.
To be marketed by Strides Pharma Inc. in the US market
Subscribe To Our Newsletter & Stay Updated
